Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:PROK NASDAQ:PRTA NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$2.85-3.2%$2.50$1.75▼$4.94$163.59M3.34781,399 shs173,336 shsPROKProKidney$1.75-1.1%$2.00$0.54▼$7.13$529.87M1.7880,048 shs168,009 shsPRTAProthena$9.57-1.1%$9.98$4.32▼$11.80$501.46M-0.23491,212 shs83,010 shsZVRAZevra Therapeutics$10.87+0.6%$9.80$7.16▼$13.16$646.36M0.881.06 million shs272,649 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-1.67%+13.08%+14.84%+28.95%+79.27%PROKProKidney-4.84%-8.29%-9.23%-11.94%+145.36%PRTAProthena-9.88%-9.12%-7.90%+7.92%+30.15%ZVRAZevra Therapeutics-2.96%+7.25%+14.04%+25.44%+37.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$2.85-3.2%$2.50$1.75▼$4.94$163.59M3.34781,399 shs173,336 shsPROKProKidney$1.75-1.1%$2.00$0.54▼$7.13$529.87M1.7880,048 shs168,009 shsPRTAProthena$9.57-1.1%$9.98$4.32▼$11.80$501.46M-0.23491,212 shs83,010 shsZVRAZevra Therapeutics$10.87+0.6%$9.80$7.16▼$13.16$646.36M0.881.06 million shs272,649 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-1.67%+13.08%+14.84%+28.95%+79.27%PROKProKidney-4.84%-8.29%-9.23%-11.94%+145.36%PRTAProthena-9.88%-9.12%-7.90%+7.92%+30.15%ZVRAZevra Therapeutics-2.96%+7.25%+14.04%+25.44%+37.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.70Moderate Buy$10.00251.49% UpsidePROKProKidney 2.50Moderate Buy$7.40322.86% UpsidePRTAProthena 2.36Hold$21.78127.68% UpsideZVRAZevra Therapeutics 2.89Moderate Buy$23.33114.68% UpsideCurrent Analyst Ratings BreakdownLatest BDTX, ZVRA, PROK, and PRTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026ZVRAZevra Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)5/8/2026ZVRAZevra Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$23.00 ➝ $25.005/8/2026PRTAProthena CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/8/2026PRTAProthena Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$19.00 ➝ $20.004/29/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/29/2026BDTXBlack Diamond Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.004/27/2026PRTAProthena Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/23/2026BDTXBlack Diamond Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)4/21/2026PROKProKidney Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/18/2026PROKProKidney Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M2.33$0.50 per share5.67$1.97 per share1.44PROKProKidney$890K593.66N/AN/A($3.36) per share-0.52PRTAProthena$9.68M51.73N/AN/A$5.21 per share1.84ZVRAZevra Therapeutics$106.47M6.04$0.92 per share11.77$2.75 per share3.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics$22.37M-$0.77N/AN/AN/AN/A-30.18%-23.91%N/APROKProKidney-$68.99M-$0.52N/AN/AN/A-7,725.20%N/A-18.83%N/APRTAProthena-$244.09M-$2.82N/AN/A0.38-260.92%-43.44%-36.87%N/AZVRAZevra Therapeutics$83.23M$1.995.499.13N/A101.58%51.49%28.86%N/ALatest BDTX, ZVRA, PROK, and PRTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18-$0.16+$0.02-$0.16$25.00 millionN/A5/7/2026Q1 2026PRTAProthena-$0.31$0.60+$0.91$0.60$0.81 million$51.08 million5/6/2026Q1 2026ZVRAZevra Therapeutics$0.06$0.18+$0.12$0.60$31.96 million$36.22 million3/18/2026Q4 2025PROKProKidney-$0.16-$0.14+$0.02-$0.13$0.00 million$0.23 million3/16/2026Q4 2025BDTXBlack Diamond Therapeutics-$0.18-$0.14+$0.04-$0.27$9.38 millionN/A2/19/2026Q4 2025PRTAProthena-$0.45-$0.44+$0.01-$0.40$0.67 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.468.46PROKProKidneyN/A9.139.13PRTAProthenaN/A10.4310.43ZVRAZevra TherapeuticsN/A4.894.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%PROKProKidney51.59%PRTAProthena97.08%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics9.29%PROKProKidney39.83%PRTAProthena10.40%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9057.30 million51.98 millionOptionablePROKProKidney3301.92 million181.66 millionOptionablePRTAProthena13052.35 million46.91 millionOptionableZVRAZevra Therapeutics2059.12 million57.70 millionOptionableBDTX, ZVRA, PROK, and PRTA HeadlinesRecent News About These CompaniesZevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference3 hours ago | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Zevra Therapeutics (ZVRA), Medicus Pharma Ltd (MDCX)May 11 at 3:27 PM | theglobeandmail.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 11 at 2:14 AM | americanbankingnews.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by BrokeragesMay 11 at 2:14 AM | marketbeat.comHC Wainwright Analysts Increase Earnings Estimates for ZVRAMay 11 at 1:21 AM | marketbeat.comZevra Therapeutics Earnings Call Highlights Growth PivotMay 10 at 8:31 PM | tipranks.comZevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextMay 9 at 7:38 PM | finance.yahoo.comResearch Analysts Offer Predictions for ZVRA Q2 EarningsMay 8, 2026 | marketbeat.comComparing TNF Pharmaceuticals (NASDAQ:TNFA) and Zevra Therapeutics (NASDAQ:ZVRA)May 8, 2026 | americanbankingnews.comZevra Therapeutics: Q1 Earnings SnapshotMay 7, 2026 | chron.comZevra (ZVRA) Q1 2026 Earnings Call TranscriptMay 7, 2026 | fool.comIs It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?May 7, 2026 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2026 Earnings Call TranscriptMay 7, 2026 | insidermonkey.comZevra Therapeutics Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comZevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comZevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass EstimatesMay 6, 2026 | zacks.comZevra Therapeutics (NASDAQ:ZVRA) Announces Earnings ResultsMay 6, 2026 | marketbeat.comZevra Reports First Quarter 2026 Financial Results and Corporate UpdateMay 6, 2026 | globenewswire.comZevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comZevra Therapeutics Announces Details for Q1 2026 Financial Results CallApril 23, 2026 | markets.businessinsider.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 16, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDTX, ZVRA, PROK, and PRTA Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$2.84 -0.10 (-3.23%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.ProKidney NASDAQ:PROK$1.75 -0.02 (-1.13%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Prothena NASDAQ:PRTA$9.56 -0.11 (-1.09%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.Zevra Therapeutics NASDAQ:ZVRA$10.87 +0.07 (+0.64%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
